echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > HER2 dual anti-KN026 combined with chemotherapy for the treatment of gastric cancer is clinically approved

    HER2 dual anti-KN026 combined with chemotherapy for the treatment of gastric cancer is clinically approved

    • Last Update: 2022-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 4, Corning Jereh and CSPC jointly announced that a registered clinical trial (KN026-CSP-001) of the HER2 bispecific antibody KN026 combined with chemotherapy has been applied for by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.


    KN026-CSP-001 is a randomized, multicenter, phase II/III clinical study to evaluate the effectiveness and safety of KN026 combined with chemotherapy in patients with HER2-positive gastric cancer (including gastric-esophageal junction adenocarcinoma) who have failed first-line treatment , Professor Xu Jianming from the General Hospital of the Chinese People’s Liberation Army served as the principal investigator


    Gastric cancer and adenocarcinoma of the gastroesophageal junction are one of the common malignant tumors.


    KN026's Phase II study data released at the ASCO annual meeting in 2021 shows that KN026 is effective in treating patients with advanced HER2-positive gastric and gastroesophageal junction adenocarcinoma, regardless of whether the patient has previously received trastuzumab therapy: in patients with high HER2 expression , The objective response rate (ORR) was 55.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.